Corrigendum: 20(S)-Ginsenoside Rg3 Promotes Senescence And Apoptosis In Gallbladder Cancer Cells Via The P53 Pathway(Drug Des Devel Ther. (2015), 9, (3969-3987), 10.2147/DDDT.S84527);20(S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 3969-3987

  Zhang, Fei ^a   Li, Maolan ^a   Wu, Xiangsong ^a   Hu, Yunping ^a   Cao, Yang ^a   Wang, Xu’An ^a   Xiang, Shanshan ^a   Li, Huaifeng ^a   Jiang, Lin ^a   Tan, Zhujun ^a   Lu, Wei ^a   Weng, Hao ^a   Shu, Yijun ^a   Gong, Wei ^a   Wang, Xuefeng ^a   Zhang, Yong ^a   Shi, Weibin ^a   Dong, Ping ^a   Gu, Jun ^a   Liu, Yingbin ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

20(S) ginsenoside Rg3; Apoptosis; Gallbladder cancer; P53 pathway; Senescence

Indexed keywords

CASPASE; GINSENOSIDE RG 3; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GINSENOSIDE; MDM2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REPRESSION; G1 PHASE CELL CYCLE CHECKPOINT; GALLBLADDER CANCER; GALLBLADDER CANCER CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; SENESCENCE; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; CELL AGING; CELL CYCLE CHECKPOINT; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GALLBLADDER NEOPLASMS; METABOLISM; MITOCHONDRION; NUDE MOUSE; PATHOLOGY; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL AGING; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; GALLBLADDER NEOPLASMS; GINSENOSIDES; HUMANS; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939782127     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S230835     Document Type: Erratum

References (38)

1. Ma MZ, Li CX, Zhang Y, et al. Long non-coding RNA HOTAIR, a c-Myc activated driver of malignancy, negatively regulates miRNA-130a in gallbladder cancer. Mol Cancer. 2014;13:156.
2. Wang JW, Peng SY, Li JT, et al. Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. Cancer Lett. 2009;281(1):71–81.
3. Li M, Zhang Z, Li X, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46(8):872–876.
4. Tan Z, Zhang S, Li M, et al. Regulation of cell proliferation and migration in gallbladder cancer by zinc finger X-chromosomal protein. Gene. 2013;528(2):261–266.
5. Hu YP, Tan ZJ, Wu XS, et al. Triptolide induces s phase arrest and apoptosis in gallbladder cancer cells. Molecules. 2014;19(2):2612–2628.
6. Liu TY, Tan ZJ, Jiang L, et al. Curcumin induces apoptosis in gallbladder carcinoma cell line GBC-SD cells. Cancer Cell Int. 2013;13(1):64.
7. American Joint Committee on Cancer. Gallbladder. In: Edge S, Byrd DR, Compton CC, Fritz AG, Trotti FL, editors. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:211–214.
8. Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol. 2012;27(4):642–653.
9. Poon PY, Kwok HH, Yue PY, et al. Cytoprotective effect of 20S-Rg3 on benzo[a]pyrene-induced DNA damage. Drug Metab Dispos. 2012;40(1):120–129.
10. Jia L, Zhao Y. Current evaluation of the millennium phytomedicine – ginseng (I): etymology, pharmacognosy, phytochemistry, market and regulations. Curr Med Chem. 2009;16(19):2475–2484.
11. Jia L, Zhao Y, Liang XJ. Current evaluation of the millennium phytomedicine – ginseng (II): collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem. 2009;16(22):2924–2942.
12. Wei X, Su F, Su X, Hu T, Hu S. Stereospecific antioxidant effects of ginsenoside Rg3 on oxidative stress induced by cyclophosphamide in mice. Fitoterapia. 2012;83(4):636–642.
13. Wei X, Chen J, Su F, Su X, Hu T, Hu S. Stereospecificity of ginsenoside Rg3 in promotion of the immune response to ovalbumin in mice. Int Immunol. 2012;24(7):465–471.
14. Park MW, Ha J, Chung SH. 20(S)-ginsenoside Rg3 enhances glucose-stimulated insulin secretion and activates AMPK. Biol Pharm Bull. 2008;31(4):748–751.
15. Liu JP, Lu D, Nicholson RC, Li PY, Wang F. Toxicity of a novel anti-tumor agent 20(S)-ginsenoside Rg3: a 26-week intramuscular repeated administration study in Beagle dogs. Food Chem Toxicol. 2011;49(8):1718–1727.
16. Liu JP, Lu D, Nicholson RC, Zhao WJ, Li PY, Wang F. Toxicity of a novel anti-tumor agent 20(S)-ginsenoside Rg3: a 26-week intramuscular repeated administration study in rats. Food Chem Toxicol. 2012;50(10):3388–3396.
17. Lee JY, Jung KH, Morgan MJ, et al. Sensitization of TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells. Mol Cancer Ther. 2013;12(3):274–285.
18. Kim DG, Jung KH, Lee DG, et al. 20(S)-Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin. Oncotarget. 2014;5(12):4438–4451.
19. Yuan HD, Quan HY, Zhang Y, Kim SH, Chung SH. 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway. Mol Med Rep. 2010;3(5):825–831.
20. Qiu XM, Bai X, Jiang HF, He P, Wang JH. 20-(s)-ginsenoside Rg3 induces apoptotic cell death in human leukemic U937 and HL-60 cells through PI3K/Akt pathways. Anticancer Drugs. 2014;25(9):1072–1080.
21. Wang JH, Nao JF, Zhang M, He P. 20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer HO-8910 cells through PI3K/Akt and XIAP pathways. Tumour Biol. 2014;25(12):11985–11994.
22. Li S, Dong P, Wang J, et al. Icariin, a natural flavonol glycoside, induces apoptosis in human hepatoma SMMC-7721 cells via a ROS/JNK-dependent mitochondrial pathway. Cancer Lett. 2010;298(2):222–230.
23. Te PR, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002;62(6):1876–1883.
24. Bao R, Shu Y, Wu X, et al. Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer. 2014;14:217.
25. Wang XA, Xiang SS, Li HF, et al. Cordycepin induces S phase arrest and apoptosis in human gallbladder cancer cells. Molecules. 2014;19(8):11350–11365.
26. Saris NE, Teplova VV, Odinokova IV, Azarashvily TS. Interference of calmidazolium with measurement of mitochondrial membrane potential using the tetraphenylphosphonium electrode or the fluorescent probe rhodamine 123. Anal Biochem. 2004;328(2):109–112.
27. Hui K, Yang Y, Shi K, et al. The p38 MAPK-regulated PKD1/CREB/Bcl-2 pathway contributes to selenite-induced colorectal cancer cell apoptosis in vitro and in vivo. Cancer Lett. 2014;354(1):189–199.
28. Kurz DJ, Decary S, Hong Y, Erusalimsky JD. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci. 2000;113(Pt 20):3613–3622.
29. Lee BY, Han JA, Im JS, et al. Senescence-associated β-galactosidase is lysosomal β-galactosidase. Aging Cell. 2006;5(2):187–195.
30. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell. 1997;91(4):443–446.
31. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2(4):466–474.
32. Kim YJ, Choi WI, Jeon BN, et al. Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-β1-induced epithelial-mesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance. Toxicology. 2014;322:23–33.
33. Ly DH, Lockhart DJ, Lerner RA, Schultz PG. Mitotic misregulation and human aging. Science. 2000;287(5462):2486–2492.
34. Salama R, Sadaie M, Hoare M, Narita M. Cellular senescence and its effector programs. Genes Dev. 2014;28(2):99–114.
35. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–310.
36. Schumacher M, Kelkel M, Dicato M, Diederich M. Gold from the sea: marine compounds as inhibitors of the hallmarks of cancer. Biotechnol Adv. 2011;29(5):531–547.
37. Xia T, Wang JC, Xu W, et al. 20S-Ginsenoside Rh2 induces apoptosis in human Leukaemia Reh cells through mitochondrial signaling pathways. Biol Pharm Bull. 2014;37(2):248–254.
38. Poyurovsky MV, Katz C, Laptenko O, et al. The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol. 2010;17(8):982–989.